Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation

• ClinicalTrials.gov Identifier: NCT02955264
• Recruitment Status: Completed
• First Posted: November 4, 2016
• Last Update Posted: January 8, 2021
• Sponsor: Tulane University
• Information provided by (Responsible Party): Tulane University

Study Description

Brief Summary:

The goal of this study is to better characterize the metabolic alterations and sugar structure alterations (glycosylation abnormalities) in patients diagnosed with Congenital Disorders of Glycosylation. The investigators aim to assess the safety and tolerability of oral galactose treatment in a small pilot group of Congenital Disorders of Glycosylation patients. The investigators will also determine the relationship between simple milk sugar intake (galactose dose) in the diet and the blood and urine markers of protein glycosylation abnormalities.

Condition or disease	Intervention/treatment	Phase
Congenital Disorders of Glycosylation	Dietary Supplement: D-Galactose	Not Applicable

Detailed Description:

The primary hypothesis in this study is that adding simple milk sugar (galactose) to the diet of Congenital Disorders of Glycosylation patients will normalize the metabolic abnormalities. The secondary hypothesis posits that galactose intervention in Congenital Disorders of Glycosylation patients will normalize specific physiological biomarkers of protein glycosylation that can be utilized for future phase II/III trial development. The knowledge gained from the investigation of these two aims will help the investigators learn more about the disrupted metabolic mechanism of this disease and should lead to the identification of new disease biomarkers that can be used to evaluate clinical efficacy in future therapeutic trials.

Over a two-year period, the investigators will enroll patients diagnosed with Congenital Disorders of Glycosylation. The investigators propose to administer oral galactose supplementation for a period of 18 weeks in increasing dose to assess its effectiveness at normalizing glycosylation. Galactose will be given in a series of doses within the range of normal dietary intake of galactose over fixed time points. To assess the effects of oral galactose supplementation for each participant, changes in participant growth, as well as blood sugar levels, coagulation parameters and liver function (the primary clinical features of Congenital Disorders of Glycosylation) will be correlated with biomarkers derived from participant blood and urine samples obtained at key time points and then compared to standard normative ranges of data for each measure.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 8 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: Dietary Supplement: D-Galactose
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation
• Actual Study Start Date: July 2014
• Actual Primary Completion Date: November 2017
• Actual Study Completion Date: January 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: D-Galactose; D-Galactose is an oral powdered supplement to be taken by mouth. For the first 6 weeks galactose will be given at the dose 0.5g per kg, then from weeks 7-12 at 1.0g per kg, lastly from weeks 13 to 18 at 1.5g per kg (with a maximum daily dose of 50g).	Dietary Supplement: D-Galactose; D-Galactose is an oral powdered dietary supplement to be taken by mouth.

Outcome Measures

Primary Outcome Measures :

1. Metabolic Function [ Time Frame: 18 weeks ]
   Assess if the introduction of galactose into the subject's diet will normalization metabolic function. Metabolic function will be based on liver function and used for muscle enzyme tests, thyroid and growth hormone measurement, coagulation and anti-coagulation factors, blood sugar and milk-acid and biochemical/metabolic parameters. These measurements will be assessed together to see how many subjects will remain with abnormal values or change to within normal levels.

Secondary Outcome Measures :

1. Biomarkers for protein glycosylation [ Time Frame: 18 weeks ]
   Identify potential biomarkers for glycosylation and metabolic dysfunction. And learn the physiological effect of adding galactose to the diet on known biomarkers for protein glycosylation. Specific biomarkers that will be examined include: transferrin glyco isoforms, antithrombin III, coagulation factor IX and XI, IGFBP3 and TSH. These measurements will be assessed together to see how many subjects will remain with abnormal values or change to within normal levels.

Eligibility Criteria

• Ages Eligible for Study: up to 21 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Biochemically and genetically proven Congenital Disorders of Glycosylation.

Exclusion Criteria:

• Any of the following conditions:
• Aldolase B Deficiency
• Galactosemia (unable to process galactose)
• Hemolytic uremic syndrome
• Severe anemia
• Diagnosis of intellectual disability or developmental delay
• Galactose Intolerance
• Has previously experienced any of the following severe side effects from oral galactose:
• Diarrhea
• Vomiting
• Constipation
• Galactosuria (Galactose in the urine)
• Increased liver glycogen storage.

Contacts and Locations

Locations

United States, Louisiana

Tulane University

New Orleans, Louisiana, United States, 70112

Sponsors and Collaborators

Tulane University

Investigators

• Principal Investigator: Eva Morava-Kozicz, MD, PhD; Mayo Clinic

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Witters P, Andersson H, Jaeken J, Tseng L, van Karnebeek CDM, Lefeber DJ, Cassiman D, Morava E. D-galactose supplementation in individuals with PMM2-CDG: results of a multicenter, open label, prospective pilot clinical trial. Orphanet J Rare Dis. 2021 Mar 20;16(1):138. doi: 10.1186/s13023-020-01609-z.

• Responsible Party: Tulane University
• ClinicalTrials.gov Identifier: NCT02955264
• Other Study ID Numbers: 14-517339
• First Posted: November 4, 2016
• Last Update Posted: January 8, 2021
• Last Verified: January 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Tulane University:

Glycosylation; Glucose Metabolic Disorder; Galactose

Additional relevant MeSH terms:

Congenital Disorders of Glycosylation; Disease; Pathologic Processes; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases